Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1917 2
1918 2
1954 1
1961 8
1962 7
1963 5
1964 10
1965 7
1966 10
1967 14
1968 10
1969 11
1970 11
1971 14
1972 4
1973 9
1974 12
1975 20
1976 16
1977 19
1978 14
1979 12
1980 15
1981 21
1982 23
1983 33
1984 20
1985 22
1986 39
1987 43
1988 52
1989 55
1990 48
1991 44
1992 40
1993 55
1994 43
1995 54
1996 60
1997 62
1998 61
1999 68
2000 62
2001 63
2002 75
2003 71
2004 105
2005 77
2006 90
2007 83
2008 77
2009 108
2010 113
2011 116
2012 111
2013 80
2014 107
2015 121
2016 133
2017 142
2018 151
2019 140
2020 185
2021 210
2022 14
Text availability
Article attribute
Article type
Publication date

Search Results

3,227 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Drilon A, et al. Among authors: goto k. N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653. N Engl J Med. 2020. PMID: 32846060 Free PMC article. Clinical Trial.
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. Kumagai S, et al. Among authors: goto k. Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31. Nat Immunol. 2020. PMID: 32868929
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Drilon A, et al. Among authors: goto k. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
Multiplex gene-panel testing for lung cancer patients.
Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Yatabe Y, et al. Among authors: goto k. Pathol Int. 2020 Dec;70(12):921-931. doi: 10.1111/pin.13023. Epub 2020 Sep 21. Pathol Int. 2020. PMID: 32956529 Review.
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M, Yoshida T, Kumagai T, Hida T, Toyozawa R, Shimokawaji T, Goto K, Nakagawa K, Ohe Y, Seto T, Kudou K, Asato T, Zhang P, Yamamoto N. Nishio M, et al. Among authors: goto k. J Thorac Oncol. 2021 Mar;16(3):452-463. doi: 10.1016/j.jtho.2020.11.004. Epub 2020 Nov 25. J Thorac Oncol. 2021. PMID: 33248320 Free article. Clinical Trial.
Effects of Physical-Agent Pain Relief Modalities for Fibromyalgia Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Honda Y, Sakamoto J, Hamaue Y, Kataoka H, Kondo Y, Sasabe R, Goto K, Fukushima T, Oga S, Sasaki R, Tanaka N, Nakano J, Okita M. Honda Y, et al. Among authors: goto k. Pain Res Manag. 2018 Oct 1;2018:2930632. doi: 10.1155/2018/2930632. eCollection 2018. Pain Res Manag. 2018. PMID: 30402199 Free PMC article. Review.
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, Frigault MM, Vishwanathan K, Ghiorghiu D, Ramalingam SS, Ahn MJ. Oxnard GR, et al. Among authors: goto k. Ann Oncol. 2020 Apr;31(4):507-516. doi: 10.1016/j.annonc.2020.01.013. Epub 2020 Jan 24. Ann Oncol. 2020. PMID: 32139298 Free article. Clinical Trial.
3,227 results